Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ustekinumab biosimilar by Biocon for Crohn's Disease (Regional Enteritis): Likelihood of Approval
Ustekinumab biosimilar is under clinical development by Biocon and currently in Pre-Registration for Crohn's Disease (Regional Enteritis). According to GlobalData,...
Itolizumab by Biocon for Coronavirus Disease 2019 (COVID-19) Pneumonia: Likelihood of Approval
Itolizumab is under clinical development by Biocon and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Pneumonia. According to...
Adalimumab biosimilar by Biocon for Plaque Psoriasis (Psoriasis Vulgaris): Likelihood of Approval
Adalimumab biosimilar is under clinical development by Biocon and currently in Phase III for Plaque Psoriasis (Psoriasis Vulgaris). According to...